The randomized controlled trial of the efficacy of goshajinkigan, mecobalamin and lafutidine in breast cancer patients with chemotherapy-induced peripheral neuropathy.

The randomized controlled trial of the efficacy of goshajinkigan, mecobalamin and lafutidine in breast cancer patients with chemotherapy-induced peripheral neuropathy. - The efficacy of goshajinkigan, mecobalamin and lafutidine in breast cancer patients with chemotherapy-induced peripheral neuropathy.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010969

Enrollment

Registered

2013-06-15

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy-induced peripheral neuropathy

Interventions

Goshajinkigan is administered orally at the dose of 2.5g three times daily for 8 weeks. Mecobalamin is administered orally at the dose of 500 microgram three times daily for 8 weeks. Lafutidine is adm

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Breast cancer patient with taxane-induced peripheral neuropathy, which continued more than 1 month after chemotherapy with taxane (paclitaxel, nab-paclitaxel, docetaxel). 2)with digestive symptom such as upper abdominal discomfort 3)written informed consent

Exclusion criteria

Exclusion criteria: 1)with severe complications (such as liver failure, renal failure, heart failure) 2)with history of allergy 3)alredy adminstered with Goshajinkigan, Mecobalamin or Lafutidine. 4)with peripheral neuropathy for other cause (such as diabetes) 5)receiving drugs to influence peripheral neuropathy 6)doctore's decision not to be registered to this study

Design outcomes

Primary

Measure	Time frame
The level of improvement of peripheral neuropathy is evaluated by Visual Analogue Scale (VAS).	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactMasahiro Kishimoto

Meiwa Hospital Department of breast and endocrine surgery

mm-kishi@hotmail.co.jp0798-47-8186

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026